Kimia Bioscien.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE285U01025
NSEID:
BSEID: 530313
View on BSE

INR

32.51

-0.53 (-1.6%)

BSENSE

Jul 17, 03:30 PM

BSE+NSE Vol: 432

{
  "main_header": {
    "sid": 263659,
    "name": "Kimia Bioscien.",
    "stock_name": "Kimia Bioscien.",
    "full_name": "Kimia Biosciences Ltd",
    "name_url": "stocks-analysis/kimia-bioscien",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "32.51",
    "chg": -0.53,
    "chgp": "-1.6%",
    "dir": -1,
    "prev_price": "33.04",
    "mcapval": "152.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530313,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE285U01025",
    "curr_date": "Jul 17, 03:30 PM",
    "curr_time": "08:55 AM",
    "last_traded_at": "Jul 17, 03:30 PM IST",
    "bse_nse_vol": "432 ",
    "exc_status": "Active",
    "traded_date": "Jul 17, 2026",
    "traded_date_str": "2026 07 17",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/kimia-bioscien-263659-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Kimia Biosciences Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kimia-biosciences-ltd-is-rated-strong-sell-4096370",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/KimiaBioscience_mojoScore_4096370.png",
        "date": "2026-07-10 10:10:30",
        "description": "Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 July 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Kimia Biosciences Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kimia-biosciences-ltd-is-rated-strong-sell-4076960",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/KimiaBioscience_mojoScore_4076960.png",
        "date": "2026-06-29 10:10:26",
        "description": "Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 June 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Kimia Biosciences Downgraded to Strong Sell Amid Weak Financials and Technical Setbacks",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kimia-biosciences-downgraded-to-strong-sell-amid-weak-financials-and-technical-setbacks-4060523",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/KimiaBioscience_mojoScore_4060523.png",
        "date": "2026-06-18 08:05:52",
        "description": "Kimia Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its quality, valuation, financial trends, and technical indicators. The downgrade reflects deteriorating fundamentals, persistent financial weakness, and a shift in technical momentum, signalling heightened risks for investors in this micro-cap pharmaceutical company."
      },
      {
        "title": "Kimia Biosciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kimia-biosciences-ltd-is-rated-sell-4054218",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/KimiaBioscience_mojoScore_4054218.png",
        "date": "2026-06-15 10:10:37",
        "description": "Kimia Biosciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 3 June 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 June 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Kimia Biosciences Ltd Falls 3.84%: 2 Key Factors Driving the Weekly Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kimia-biosciences-ltd-falls-384-2-key-factors-driving-the-weekly-decline-4053073",
        "imagepath": "",
        "date": "2026-06-14 14:01:25",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>1 June:</strong> Stock opens sharply lower at Rs.33.29 (-8.79%) amid broad market weakness</p>\n                    <p><strong>2 June:</strong> Formation of Golden Cross signals potential bullish breakout despite price decline</p>\n                    <p><strong>4 June:</strong> MarketsMOJO downgrades rating from Strong Sell to Sell citing financial deterioration</p>\n                    <p><strong>5 June:</strong> Stock rebounds to Rs.35.10 (+6.01%) on increased volume but closes below week open</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.36.50</div></..."
      },
      {
        "title": "Kimia Biosciences Ltd Downgraded to Sell Amid Financial and Technical Shifts",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kimia-biosciences-ltd-downgraded-to-sell-amid-financial-and-technical-shifts-4035386",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/KimiaBioscience_mojoScore_4035386.png",
        "date": "2026-06-04 08:07:12",
        "description": "Kimia Biosciences Ltd has seen its investment rating downgraded from Strong Sell to Sell as of 3 June 2026, reflecting deteriorating financial performance and mixed technical signals. Despite a modest uptick in daily share price, the company faces significant challenges across quality, valuation, financial trends, and technical indicators, prompting a reassessment of its market standing within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Golden Cross Forms in Kimia Biosciences Ltd — On a Day the Stock Fell 1.35%. What the Mixed Signals Mean",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kimia-biosciences-ltd-forms-golden-cross-indicating-potential-bullish-breakout-4031711",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/KimiaBioscience_goldencross_4031711.png",
        "date": "2026-06-02 18:20:06",
        "description": "The 50-day moving average has crossed above the 200-day moving average for Kimia Biosciences Ltd, signalling a golden cross on 2 Jun 2026. Yet, the stock declined 1.35% on the same day, while monthly technical indicators remain bearish. This juxtaposition of signals calls for a detailed examination of the cross’s reliability."
      },
      {
        "title": "Are Kimia Biosciences Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-kimia-biosciences-ltd-latest-results-good-or-bad-4023719",
        "imagepath": "",
        "date": "2026-05-30 19:39:08",
        "description": "Kimia Biosciences Ltd's latest financial results for Q4 FY26 indicate significant operational challenges. The company reported net sales of ₹27.20 crores, reflecting a 9.63% decline from the previous quarter and a more substantial 28.87% decrease year-on-year. This revenue contraction is accompanied by a sharp drop in net profit, which fell to ₹0.37 crores, marking a 93.20% decline compared to the prior quarter and an 81.41% decrease year-on-year. \n\nThe profit after tax (PAT) margin has compressed to 1.36%, down from 5.20% in the same quarter last year, while the operating margin also deteriorated from 21.39% to 9.82%. These figures suggest that the company is experiencing severe pricing pressures or cost management issues. Additionally, the effective tax rate of 78.98% raises concerns about the sustainability of the company's tax position and may indicate one-time adjustments impacting the bottom line.\n\nFo..."
      },
      {
        "title": "Kimia Biosciences Q4 FY26: Profit Plunges 81% as Margins Collapse Despite Revenue Resilience",
        "link": "https://www.marketsmojo.com/news/result-analysis/kimia-biosciences-q4-fy26-profit-plunges-81-as-margins-collapse-despite-revenue-resilience-4022961",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/KimiaBioscience_quaterlyResult_4022961.png",
        "date": "2026-05-29 23:46:47",
        "description": "Kimia Biosciences Ltd., a micro-cap pharmaceutical company specialising in bulk drug manufacturing, reported a dramatic 81.41% quarter-on-quarter decline in net profit for Q4 FY26, posting ₹0.37 crores compared to ₹1.99 crores in Q4 FY25. The sharp earnings contraction occurred despite relatively stable revenue performance, with net sales declining 28.87% year-on-year to ₹27.20 crores. The stock, currently trading at ₹36.50 with a market capitalisation of ₹168.00 crores, has struggled over the past year, delivering negative returns of 27.01% whilst the broader pharmaceuticals sector gained 9.25%."
      }
    ],
    "total": 201,
    "sid": "263659",
    "stock_news_url": "https://www.marketsmojo.com/news/kimia-biosciences-263659"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "27-Jun-2026",
      "details": "Closure of Trading window for quarter ending June 30 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "01-Jun-2026",
      "details": "Publication of Results for quarter and year ended March 31 2026",
      "source": "BSE"
    },
    {
      "caption": "Outcome Of The Board Meeting Held On 29 May 2026",
      "datetime": "29-May-2026",
      "details": "Approval of Audited standalone Financial results alongwith Audited Report thereon for financial year 2025-26",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Kimia Biosciences Ltd is Rated Strong Sell

2026-07-10 10:10:30

Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 July 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Kimia Biosciences Ltd is Rated Strong Sell

2026-06-29 10:10:26

Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Kimia Biosciences Downgraded to Strong Sell Amid Weak Financials and Technical Setbacks

2026-06-18 08:05:52

Kimia Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its quality, valuation, financial trends, and technical indicators. The downgrade reflects deteriorating fundamentals, persistent financial weakness, and a shift in technical momentum, signalling heightened risks for investors in this micro-cap pharmaceutical company.

Read full news article

Kimia Biosciences Ltd is Rated Sell

2026-06-15 10:10:37

Kimia Biosciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 3 June 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Kimia Biosciences Ltd Falls 3.84%: 2 Key Factors Driving the Weekly Decline

2026-06-14 14:01:25

Key Events This Week

1 June: Stock opens sharply lower at Rs.33.29 (-8.79%) amid broad market weakness

2 June: Formation of Golden Cross signals potential bullish breakout despite price decline

4 June: MarketsMOJO downgrades rating from Strong Sell to Sell citing financial deterioration

5 June: Stock rebounds to Rs.35.10 (+6.01%) on increased volume but closes below week open

Week Open

Rs.36.50

Read full news article

Kimia Biosciences Ltd Downgraded to Sell Amid Financial and Technical Shifts

2026-06-04 08:07:12

Kimia Biosciences Ltd has seen its investment rating downgraded from Strong Sell to Sell as of 3 June 2026, reflecting deteriorating financial performance and mixed technical signals. Despite a modest uptick in daily share price, the company faces significant challenges across quality, valuation, financial trends, and technical indicators, prompting a reassessment of its market standing within the Pharmaceuticals & Biotechnology sector.

Read full news article

Golden Cross Forms in Kimia Biosciences Ltd — On a Day the Stock Fell 1.35%. What the Mixed Signals Mean

2026-06-02 18:20:06

The 50-day moving average has crossed above the 200-day moving average for Kimia Biosciences Ltd, signalling a golden cross on 2 Jun 2026. Yet, the stock declined 1.35% on the same day, while monthly technical indicators remain bearish. This juxtaposition of signals calls for a detailed examination of the cross’s reliability.

Read full news article

Are Kimia Biosciences Ltd latest results good or bad?

2026-05-30 19:39:08

Kimia Biosciences Ltd's latest financial results for Q4 FY26 indicate significant operational challenges. The company reported net sales of ₹27.20 crores, reflecting a 9.63% decline from the previous quarter and a more substantial 28.87% decrease year-on-year. This revenue contraction is accompanied by a sharp drop in net profit, which fell to ₹0.37 crores, marking a 93.20% decline compared to the prior quarter and an 81.41% decrease year-on-year. The profit after tax (PAT) margin has compressed to 1.36%, down from 5.20% in the same quarter last year, while the operating margin also deteriorated from 21.39% to 9.82%. These figures suggest that the company is experiencing severe pricing pressures or cost management issues. Additionally, the effective tax rate of 78.98% raises concerns about the sustainability of the company's tax position and may indicate one-time adjustments impacting the bottom line. Fo...

Read full news article

Kimia Biosciences Q4 FY26: Profit Plunges 81% as Margins Collapse Despite Revenue Resilience

2026-05-29 23:46:47

Kimia Biosciences Ltd., a micro-cap pharmaceutical company specialising in bulk drug manufacturing, reported a dramatic 81.41% quarter-on-quarter decline in net profit for Q4 FY26, posting ₹0.37 crores compared to ₹1.99 crores in Q4 FY25. The sharp earnings contraction occurred despite relatively stable revenue performance, with net sales declining 28.87% year-on-year to ₹27.20 crores. The stock, currently trading at ₹36.50 with a market capitalisation of ₹168.00 crores, has struggled over the past year, delivering negative returns of 27.01% whilst the broader pharmaceuticals sector gained 9.25%.